Navigation Links
Cambridge Semantics to Present on Smart Data and Competitive Intelligence Informatics at 2013 Pharma CI Conference & Exposition

BOSTON (PRWEB) August 22, 2013

Cambridge Semantics, leading provider of smart data solutions for the pharmaceutical industry, today announced its participation in the 2013 Pharma CI Conference & Exposition. Lee Feigenbaum, Vice President of Marketing and Technology for Cambridge Semantics, will present on pharma competitive intelligence (CI) solutions to automate data gathering, investigation and analytics to conference delegates. In addition, Cambridge Semantics is exhibiting at the conference.

September 18, 2013
9:00 a.m. – 9:35 a.m.

Pharma CI Conference & Exhibition
Hilton East Brunswick Hotel
3 Tower Center Blvd.
East Brunswick, New Jersey 08816

Details: Large pharmaceutical organizations, like companies in many industries, face challenges with enterprise data management and end user data consumption. At Pharma CI Conference & Exposition, Feigenbaum’s presentation will introduce the concept of “CI Informatics,” technology solutions dedicated to gathering and distributing high-quality competitive intelligence information. Feigenbaum’s presentation will provide examples of CI Informatics in use based on Cambridge Semantics’ award-winning Anzo Pharma Competitive Intelligence solution.

Using semantic technology, Anzo proactively gathers and routes relevant and targeted CI information to the right people at the right time, from the right information sources – whether internal or external to the company, structured or unstructured. The software can be used for intelligence gathering across a number of use cases, including compound licensing, biopartnering, market intelligence, comparative effectiveness research, drug repositioning, self-service competitive intelligence reporting and analytics, and more.

Cambridge Semantics’ Anzo platform has been deployed by R&D CI teams, business development and sourcing teams, marketing groups and knowledge management teams at a number of leading pharma companies, including Merck, Lilly, Novartis, Biogen and others.

Media and analysts interested in a briefing with Cambridge Semantics, please contact Lora Friedrichsen at Cambridge(at)globalresultspr(dot)com or +1 949 608 0276.

About Cambridge Semantics

Cambridge Semantics is privately held and based in Boston, Massachusetts. For more information visit or follow us on Twitter @CamSemantics or Facebook.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioMed Realty Acquires 320 Charles In Cambridge, MA
2. Cambridge Semantics to Highlight Innovations in Drug Safety and Business Development at DIA 2013
3. Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill
4. Cambridge Semantics Wins SIIA Software CODiE Award for Best Business Intelligence and Analytics Solution
5. Industry Leader Linguamatics Hosts Record-breaking Spring Users Conference in Cambridge, UK
6. Cambridge Semantics to Present the Case for Unified Information Access at Enterprise Data World 2013
7. Cambridge College School of Management Program Hosts a Panel Discussion On Trends and Opportunities In Health Information Technology
8. Cambridge Semantics to Speak at 2013 Bio-IT World Conference & Expo
9. Cambridge Semantics Named 2013 SIIA CODiE Award Finalist
10. P&P Optica Invited to Cambridge Innovation Centre for the Canadian Technology Accelerator Program, One of Eight Canadian Life Science Companies Chosen to Participate
11. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):